


 Cite this: *RSC Adv.*, 2019, 9, 11707

iTRAQ based proteomic analysis of PM_{2.5} induced lung damage

 Zhaohui Xue,^{†a} Ang Li,^{†a} Xueya Zhang,^{†a} Wancong Yu,^b Junyu Wang,^a Yixia Zhang,^a Xin Gao^a and Xiaohong Kou^{*a}

Haze pollution has become a global environmental problem, subsequently affecting air quality, climate, economy and human health. Notably, PM_{2.5} (particulate matter with an aerodynamic diameter less than 2.5 micrometers) significantly accounts for a variety of adverse health effects, in particular pulmonary diseases such as asthma and lung cancer. Clinical diagnosis and medical treatment of the lung damage caused by PM_{2.5} still remain significant challenges due to the lack of specific biomarkers and pathways. Here, we established a rat model of nonsurgical intratracheal instillation to investigate PM_{2.5} exposure and employed iTRAQ based analytical technique and bioinformatics tools to identify putative biomarkers and pathways. We identified 163 differentially expressed proteins (DEPs). Among these proteins, we screened six DEPs (HMOX1, MP2K5, XRCC1, E9PTZ7, KNT2 and A1AG) as the putative biomarkers, with significant differentially expressed levels (percentage increment > 140%). Pathway analysis indicated that calcium signaling, MAPK and PI3K/AKT might be involved in the process of PM_{2.5}-induced lung damage. Western-blotting was used to verify DEPs in the AEC-II cell model for early diagnosis. In summary, our data can serve as fundamental research clues for further studies of PM_{2.5}-induced toxicity in the lungs.

Received 11th January 2019

Accepted 29th March 2019

DOI: 10.1039/c9ra00252a

rsc.li/rsc-advances

1. Introduction

In recent years, haze pollution has caused an extremely severe environmental crisis in developing countries, especially in China.¹ Among all kinds of carcinogens, particulate matter with an aerodynamic diameter of less than 2.5 μm (PM_{2.5}) shows the most adverse effects on health, attracting an increasing number of global concerns.^{2,3} More than 800 million people are exposed to haze pollution, and approximately 7 million premature deaths happened in 2012.^{4,5} A growing number of investigations demonstrated that the morbidity and mortality of lung cancer was significantly increased due to haze pollution.^{6,7} In detail, an increase of 10 μg m⁻³ of PM_{2.5} produced an increment of 4–6% overall mortality, 10% cardiovascular disease prevalence and 22% lung cancer prevalence.^{8,9} In particular, in North China cities such as Beijing and Tianjin haze pollution is much more serious than that in South China cities such as Shanghai and Guangzhou, resulting in life expectancy in North China being about 5.5 years lower than in South China.¹⁰

Although all parties have made a lot of efforts, for example, the Chinese State Council set the goal to reduce the concentration of PM_{2.5} to 60 μg m⁻³ by 2017,¹¹ billions of people still suffer from

a series of lung diseases caused by haze pollution. Therefore, the diagnostic and therapeutic solutions for PM_{2.5}-induced lung damage in the early stage are urgently needed. However, traditional diagnostic methods such as multiple CT scans and lung biopsies are risky and only available for advanced stage.¹² On the other hand, clinical treatments for lung cancer at advanced stage including surgery, radiation and chemotherapy are less effective and have side effects.¹³ To address these challenges, this paper combines a set of novel analytical methods and bioinformatics tools to screen differentially expressed proteins (DEPs), analyze these DEPs and construct pathways. We established a rat model of nonsurgical intratracheal instillation and employed Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) coupled with LC-MS/MS to analyze DEPs. iTRAQ based proteomics has proved to be one of the state-of-the-art quantitative techniques for protein profiling.^{14–16} We profiled DEPs of PM_{2.5} exposed lung tissue, identified significant DEPs as biomarkers and further analyzed biological maps of pathways. Western-blot method was used to determine the relative expression of DEPs such as HMOX1, MP2K5, E9PTZ7, XRCC1, A1AG and KNT2.

2. Materials and methods

2.1 PM_{2.5} collection

PM_{2.5} samples were collected by using three air samplers simultaneously in Tianjin, China, from June 2014 to January 2015. PM_{2.5} samples were dispersed in MQ water from Millipore Sigma (St. Louis, MO, USA), sonicated for 20 minutes, then

^aSchool of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China. E-mail: kouxiaohong@tju.edu.cn

^bMedical Plant Lab, Tianjin Research Center of Agricultural Biotechnology, Tianjin 300381, China

[†] These authors contributed equally to this paper.



filtered through six layers of sterile gauze, centrifuged and lyophilized. 300 samples were collected. Prior to use, PM_{2.5} was dispersed in sterilized 0.9% physiological saline.

2.2 PM_{2.5} exposure

Healthy adult, clean-grade male SD rats, weighing 180–200 g, were purchased from the Animal Center of Tianjin and were acclimated for one week. The rats were housed in metallic cages under standard conditions (24 ± 2 °C and 50 ± 5% humidity). We randomly divided rats into two groups, control group and PM_{2.5} group, and each group contained 10 rats. We employed a nonsurgical intratracheal instillation method to investigate PM_{2.5} exposure.^{17,18} The rats in PM_{2.5} group were intratracheally instilled with 15.0 mg per kg b.w. PM_{2.5}, while rats in control group were treated with the same dose of saline by intratracheal instillation. The instillation was performed once every 5 days. All rats received regular food and water during the whole period of the experiment. Rats were fasted 24 hours after the last instillation and then killed with aortic blood method.^{19,20} After the chest cavity was opened, lung tissues were harvested, then quick-frozen and stored at –80 °C. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Tianjin University and approved by the Animal Ethics Committee of China Research Institute of Medical Biology.

2.3 Histological evaluation

Harvested lung tissues were excised into small pieces and immediately fixed in 4% paraformaldehyde in phosphate-buffered saline (pH 7.4) for hematoxylin/eosin (H&E) staining.²¹ After paraffin embedding, sections were H and E stained, and pathomorphological lung changes were photographed using a digital camera mounted on a light microscope (BX 51; Olympus, Tokyo, Japan). Pathology scores were based on pulmonary interstitial edema, alveolar edema, inflammatory cell infiltration, alveolar haemorrhage, hyaline membrane formation, pulmonary atelectasis *etc.*

2.4 Protein extraction and digestion

The lung tissues were powdered with liquid nitrogen and sonicated in urea lysis buffer (50 mM Tris 8.0, 8 M urea, 1% NP40, 1% sodium deoxycholate, 2 mM EDTA, 5 mM DTT and 1/100 protease inhibitor cocktail, Solarbio, Beijing, China). After centrifugation, the protein concentration in the supernatant was measured using the 2-D Quant Kit from GE Healthcare (Little Chalfont, Buckinghamshire, UK). The protein was reduced with 5 mM DTT, alkylated with 30 mM IAM and precipitated with ice-cold acetone. Protein precipitate was redissolved in 0.1 M TEAB from Sigma-Aldrich (St. Louis, MO, USA) and digested with 1/25 trypsin at 37 °C overnight. The ultimate peptide was desalted with Strata X C18 SPE column (Los Angeles, California, USA) and vacuum-dried.

2.5 iTRAQ labeling

The dried peptide was reconstituted in 20 µL 0.5 M TEAB and processed by following the manufacturer's protocol (iTRAQ

8plex kit, AB Sciex). Briefly, iTRAQ reagent was thawed and reconstituted in 70 µL acetonitrile. Peptide and reagent were mixed and incubated at room temperature for 1 hour and then dried by vacuum centrifugation.

2.6 Pre-separation of tryptic peptides

The labeled peptide was mixed and fractionated with LC20AD HPLC. Then, peptide was reconstituted in buffer A (100% H₂O, pH 10.0) and loaded into a column (4.6 × 250 mm, XBridge Shield C18 RP, Waters). The peptide was eluted at a flow rate of 1 mL min^{–1} with a gradient of 5–12% buffer B (80% ACN, pH 10.0) for 20 min, 12–35% buffer B for 45 min, 35–80% buffer B for 5 min. Subsequently, the system was maintained in 80% buffer B for 5 min before equilibrating with 5% buffer B. The elution was monitored by measuring absorbance at 214 nm, and fractions were collected every 1 min. The eluted peptide was combined into 20 fractions and dried under vacuum.


2.7 LC/MS analysis

The lyophilized peptide was resuspended in buffer A (2% ACN, 0.1% FA), loaded onto an Acclaim PepMap 100 C18 trap column (75 µm × 2 cm, Dionex, Waltham, MA, USA) with Ultimate 3000 nanoUPLC (Dionex) and eluted onto an Acclaim PepMap RSLC C18 analytical column (Dionex, 75 µm × 25 cm). Buffer A linear gradient was run at 300 nL min^{–1} for 45 min, starting from 11% to 20% buffer B, followed by 2 min gradient to 80% buffer B, and maintained at 80% buffer B for 3 min. The peptide was subjected to NSI source in mass spectrometry Q Exactive plus (Waltham, MA, USA) coupled online to the UPLC. MS1 spectra were acquired at the resolution of 70 000 (at 200 *m/z*) with an AGC (automatic gain control) of 3 000 000 and a max IT of 250 ms. MS/MS data were acquired at the resolution of 17 500 through isolation windows of 2 Da, and the AGC and max IT were set to 100 000 and 100 ms, the NCE (normalized collision energy) was set to 28%. And the loop count was set to 15 which means 15 MS/MS scans would be acquired between each full scan.

2.8 Protein identification

Protein identification and quantification were performed using the Paragon Algorithm and further process using the Pro Group™ algorithm were implemented in Protein Pilot™ v4.0 software (ABI-MDS Sciex). The raw data were converted to mascot generic file using Proteome Discoverer (Waltham, MA, USA) and processed with Mascot search engine (Matrix Science, v.2.3.02). Tandem mass spectra were searched against UniProt rat reference proteome database (32 983 sequences). The mass error was set to 10 ppm for precursor ions and 0.02 Da for fragment ions. Carbamidomethyl (C), iTRAQ 8plex (K and N-term) was specified as fixed modification, oxidation (M) and iTRAQ 8plex (Y) was specified as variable modification. The decoy (reverse) database was searched to estimate the false discovery rate (FDR). The results were revalued by algorithm percolator, and PSMs (peptide-spectrum match) with unused score of >1.3 corresponded to a peptide confidence level of >95%, and a *p*-value < 0.05. Notably particularly, for quantitation, a protein must have at least two unique peptides above





E

Groups	Grades	pulmonary interstitial edema	alveolar edema	inflammatory cell infiltration	alveolar haemorrhage	Hyaline membrane formation	pulmonary atelectasis
Control		0	0	0	0	0	0
PM _{2.5}		0	0	2	1	0	1

Fig. 1 Pulmonary histological evaluation and pathological scores. The lung tissues of control group ((A and B) 10 \times magnification and 40 \times magnification, respectively) and PM_{2.5} group ((C and D) 10 \times magnification and 40 \times magnification, respectively) were stained with haematoxylin–eosin (H&E). Compared with the control group, there were a large number of inflammatory cells around bronchus in PM_{2.5} group (as shown in the black arrow); the structure of bronchial columnar epithelial cells was filled with inflammatory cells (as shown in the red arrow); the monolayer structure of the local alveolar epithelial cell wall disappeared. Epithelial cells thickened, and they aggregated into clusters of three to four layers (as shown in the yellow arrow); partial alveolar atrophied and collapsed (as shown in the brick red arrow); partial were compensatory hypertrophy (as shown in the green arrow). (E) Pathological scores.




Fig. 2 Construction of experimental model and iTRAQ based proteomics system. The process included five clusters: PM_{2.5} exposure, peptide fractions from lung protein, iTRAQ/LC-MS analysis, data analysis and bioinformatics analysis, and Western blotting.






Fig. 3 Analysis of DEPs and screening of biomarkers. The red lines represented significant DEPs with PI > 140%.

identity. The protein ratio type was weighted, the normalization method was median.

2.9 Bioinformatics analysis

Identified proteins were assigned as biological processes based on Gene Ontology (GO). Protein classification and analysis were performed with evolutionary relationships (PANTHER), a classification system v 9.0 (<http://www.pantherdb.org/>). Functional interaction networks were identified with the STRING program v 9.1 STRING (<http://string-db.org/>). On the other hand, we searched for all differentially expressed proteins and used the recommended and alternative names assigned to each protein in the UniProtKB database, and detected biological maps of pathway with the Kyoto Encyclopedia of Genes and Genomes (KEGG) (<http://www.genome.jp/kegg/>).

2.10 Western-blot

Differentially expressed proteins such as HMOX1, MP2K5, XRCC1 and A1AG were measured by Western blot. Human lung AEC-II cells (Lanmeng Biotechnology, Hebei, China) were harvested after the treatments. After lysis for 30 min on ice with Cell Protein Extraction Reagent, the total protein concentration was determined by BCA assay according to the manufacturer's instructions. Each sample containing approximately 50 µg of proteins was electrophoresed on 12% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk for 2 h at room temperature. Primary antibodies (DF6623, AF5393, AF0296, DF7667, Affinity Biosciences, OH, USA) were incubated at 4 °C overnight. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (ZB-2306, ZB-2305, ZSGB-BIO, Beijing, China). The immunoreactive bands were detected with

Table 1 Significant DEPs of lung damage induced by PM_{2.5} exposure

Entry name	Protein names	Gene names	Percentage increase (<i>I</i>)	Expressed pattern	Molecular function
HMOX1-RAT	Heme oxygenase 1	Hmox1	141.30%	↑	Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin
XRCC1_RAT	DNA repair protein XRCC1	Xrcc1	214.30%	↑	Repair DNA from oxidative damage and genetic variation
MP2K5_RAT	MAP kinase kinase 5	Map2k5	158.10%	↑	Protecting cells from stress-induced apoptosis
E9PTZ7_RAT	Protein RT1-CE12	RT1-CE1	356.40%	↑	Antigen processing and presentation of peptide antigen <i>via</i> MHC class I
A1AG_RAT	Alpha-1-acid glycoprotein	Orm1	159.50%	↑	Functions as transport protein in the blood stream. Appears to function in modulating the activity of the immune system during the acute-phase reaction
KNT2_RAT	T-kininogen 2	N/A	207.20%	↑	They effect smooth muscle contraction, induction of hypotension






Fig. 4 (a) Classification of molecular functions of DEPs. (b) DEPs enriched in response to stimulus and immune system process. Red balls represented down-regulated proteins and green balls referred to up-regulated proteins; blue words meant proteins exclusively enriched in response to stimulus, brown words were proteins exclusively enriched in immune system response, and black words denoted proteins enriched in both biology processes.

an enhanced chemiluminescent (ECL) reagent kit according to the manufacturer's protocol and a chemiluminescence detection system. The obtained images were analyzed by Image J software to analyze the gray value of the target bands for relative quantitative information analysis of the proteins.

3. Results and discussion

3.1 Effects of PM_{2.5} on lung histology and damage

Pulmonary histological evaluation and pathological scores are shown in Fig. 1. The lung of control group showed a clear structure and normal histopathology, and few inflammatory cells could be found in bronchus and bronchiolitis. In contrast, there were a large number of inflammatory cells around bronchus in PM_{2.5} group (as

shown in the black arrow); the structure of bronchial columnar epithelial cells was filled with inflammatory cells (as shown in the red arrow); the monolayer structure of the local alveolar epithelial cell wall disappeared. Epithelial cells thickened, and they aggregated into clusters of three to four layers (as shown in the yellow arrow); partial alveolar atrophied and collapsed (as shown in the brick red arrow); partial were compensatory hypertrophy (as shown in the green arrow). According to the pulmonary histological evaluation, we knew that PM_{2.5} could cause lung damage.

3.2 Construction of experimental model and iTRAQ based proteomics system

We established a rat model of nonsurgical intratracheal instillation to study the lung damage caused by PM_{2.5}. The process



Table 2 DEPs enriched in the biological functions of stimulus and immune

Entry name	Protein names	Gene names	PM _{2.5} /control	Expressed pattern	Molecular function
HA2B_RAT	RT1 class II antigen, Ba chain	RT1-Ba	0.736	↓	Antigen processing and presentation
PRG2_RAT	Proteoglycan 2	Prg2	0.714	↓	Defense response to bacterium
XRCC1_RAT	DNA repair protein XRCC1	Xrcc1	3.143	↑	Repair DNA from oxidative damage and genetic variation
CD48_RAT	CD48 antigen	Cd48	1.32	↑	Mast cell and T cell activation
YES_RAT	Tyrosine-protein kinase Yes	Yes1	0.742	↓	Regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation
MAAI_RAT	Maleylacetoacetate isomerase	Gstz1	0.738	↓	Glutathione transferase activity, L-phenylalanine catabolic process
HSPB6_RAT	Heat shock protein beta-6	Hspb6	0.676	↓	Regulation of muscle contraction
CHIA_RAT	Acidic mammalian chitinase	Chia	1.507	↑	Defense against nematodes, fungi and other pathogens
CO4_RAT	Complement C4	C4	1.345	↑	Complement activation; inflammatory response
HPT_RAT	Haptoglobin	Hp	1.757	↑	Acute inflammatory response
MP2K5_RAT	MAP kinase kinase 5	Map2k5	2.581	↑	Protecting cells from stress-induced apoptosis
F1LQ12_RAT	Protein Vom2r46	Vom2r46	1.496	↑	Detect massive pheromones
G3V6G1_RAT	Immunoglobulin joining chain	Jchain	1.433	↑	Synthesize and transport Igs
A2MG_RAT	Alpha-2-macroglobulin	A2m	1.886	↑	Acute inflammatory response to antigenic stimulus
Q5M849_RAT	Interferon-induced protein 35	Ifi35	1.39	↑	Trans located to the nucleus <i>via</i> the stimulation of interferons
AQP5_RAT	Aquaporin-5	Aqp5	0.525	↓	Generation of pulmonary secretions
BPIB1_RAT	BPI fold-containing family B member 1	Bpifb1	1.419	↑	Innate immunity in nose and lungs
TIMP3_RAT	Metalloproteinase inhibitor 3	Timp3	1.356	↑	Response to organic substance and tissue regeneration
E9PTZ7_RAT	Protein RT1-CE12	RT1-CE1	4.564	↑	Antigen processing and presentation of peptide antigen <i>via</i> MHC class I
D3ZSY4_RAT	Eosinophil peroxidase	Epx	0.738	↓	Eosinophil migration and oxidative stress
TAP2_RAT	Antigen peptide transporter 2	Tap2	0.582	↓	Adaptive immune response, antigen processing and presentation <i>via</i> MHC class I

mainly included four clusters: PM_{2.5} exposure, sample preparation, iTRAQ/LC-MS analysis and bio-information analysis (Fig. 2). PM_{2.5} was collected using air sampler in Tianjin (one of the cities in North China which was suffered severe haze pollution) from June 2014 to January 2015, a typical haze season with PM_{2.5} index ranging from 60–300 µg m⁻³. PM_{2.5} samples were dispersed in 0.9% physiological saline. Intratracheal instillation of PM_{2.5} solution was performed 3 times in 15 days on rats. After instillation, rats were anesthetized and sacrificed. Afterwards, lung tissue was harvested, followed with protein extraction. iTRAQ labeling was conducted after peptide digestion. HPLC and LC-MS were used to pre-separate and separate peptides, respectively. It was noted that iTRAQ labeling, HPLC and LC-MS were performed by an analysis specialist in a double-blind manner. In detail, after we prepared the analysis samples, we transferred the samples to the analysis specialist without exposing sample information. Afterwards, the analysis specialist carried out iTRAQ labeling, HPLC and LC-MS. We next employed the paragon algorithm to quantify proteins, following with bio-information analysis. We categorized DEPs into biological processes with the Gene Ontology (GO) program.

Furthermore, we identified functional interaction networks with the STRING program and discovered the pathways related to PM_{2.5}-induced lung damage using the Kyoto Encyclopedia of Genes and Genomes (KEGG).

3.3 Protein identification and biomarker screening

At first, we identified DEPs of PM_{2.5}-induced lung damage as candidates for biomarkers. We set the healthy rats without PM_{2.5} exposure as the control group. The ratio of protein expression of PM_{2.5} exposure group/control group was utilized to evaluate the protein expression level. We defined the cut-off ratio values of >1.3 and <0.77 (with more than 95% in confidence) as up-regulation and down-regulation, respectively. We discovered 163 DEPs in response to intratracheal instillation of PM_{2.5}, including 83 up-regulated proteins and 80 down-regulated proteins (Fig. 3). Increased percentage of DEPs (PI) was defined to evaluate the protein expression level by using the following equation: PI = (A₁ – A₀)/A₀ × 100%, where A₁ was the expression level of PM_{2.5} exposure group and A₀ was the expression level of control group. The protein with a difference






Fig. 5 Protein-protein interaction networks of DEPs. Disconnected nodes were hidden in the network. The small notes represented proteins whose 3D structure were unknown, while large notes represented proteins whose 3D structure were known or predicted. Edges represented protein-protein associations in the high confidence of 0.7.

of more than 2 times the expression level ($PI > 100\%$) was a minority compared to the overall data. A differential protein with a growth rate of $PI > 140\%$ was used as a DEP for lung injury induced by $PM_{2.5}$ exposure. Among these 163 DEPs, it was apparent that six proteins, heme oxygenase 1 (HMOX1), MAP kinase kinase 5 (MP2K5), DNA repair protein (XRCC1), protein RT1-CE12 (E9PTZ7), alpha-1-acid glycoprotein (A1AG) and T-kininogen 2 (KNT2) were significant DEPs with $PI > 140\%$ (see detailed information in Table 1).

3.4 Classification and networking of functional DEPs

In order to obtain a fundamental understanding of pathways, we next performed GO program to classify DEPs to achieve a global view of protein functions.^{22,23} In the analysis of the GO program, proteins were attributed to involve in specific biological processes. We categorized these biological processes into six significant clusters based on functions including metabolic process, cellular process, biological regulation, response to stimulus, localization and immune system process (Fig. 4a). In general, when suffering exogenous damage, the organisms

usually response to the stimulus and immune system process significantly.²⁴ GO analysis showed that eighteen proteins were enriched in response to the stimulus, fifteen proteins in the immune system process, and twelve proteins in both processes (Fig. 4b, and see detailed information in Table 2). These results indicated that response to stimulus was closely related to immune system process. Previous studies provided implications on this relevance. For example, it has been reported that oxidative stress stimulus induced by $PM_{2.5}$ exposure stimulated inflammatory responses, coupled with oxidative stress stimulus, further leading to cell apoptosis and immune response.^{25,26} We further analyzed the network of protein-protein interactions between DEPs through STRING program. We obtained 16 protein clusters (Fig. 5, and see detailed functions of protein clusters in Table 3).

The analysis results implied that cluster 4, 5, 8, 11 were associated with antioxidant activity and cluster 1, 2, 3, 6, 9, 12, 15 were relevant with inflammatory response and immune regulation (Table 4). The above analysis showed that oxidative stress stimulus, inflammatory response and immune regulation were the most responsible factors for $PM_{2.5}$ -induced lung damage.



Table 3 Interaction networks of DEPs

Cluster number	Entry name	Protein name	Number	Function of protein cluster
1	G3V6G1_RAT, LAC2_RAT	Ig lambda-2 chain C region, protein Jchain	2	Adaptive immune response
2	F1LR39_RAT, Q6VEU8_RAT	WD repeat-containing protein 18, protein Ddx24	2	Major pathway of rRNA processing in the nucleolus
3	E9PTZ7_RAT, Q6MGB8_RAT	Protein RT1-CE12, protein RT1-A2	2	Involved in the presentation of foreign antigens to the immune system
4	Q5RJN0_RAT, NDUA_A_RAT	Protein Ndufs7, NADH-ubiquinone oxidoreductase 42 kDa subunit	2	Mitochondrial electron transport, NADH to ubiquinone
5	F1LTB8_RAT, B2GV28_RAT	UDP-glucuronosyltransferase, cytochrome P450 2B1	2	Involved in an NADPH-dependent electron transport pathway
6	HMOX1_RAT, NGAL_RAT	Heme oxygenase 1, neutrophil gelatinase-associated lipocalin	2	Sensitive indicator of inflammatory damage
7	O88753_RAT, O88752_RAT	Epsilon 2 globin, epsilon 1 globin	2	Hemoglobin subunit epsilon
8	PGAM2_RAT, MYG_RAT, HPT_RAT	Phosphoglycerate mutase 2, myoglobin, haptoglobin	3	Reduced activity or antioxidant activity, serves as a reserve supply of oxygen
9	GNPAT_RAT, Q6MG85_RAT	Dihydroxyacetone phosphate acyltransferase, 1-acyl-sn-glycerol-3-phosphate acyltransferase	2	Synthesis of PA, CDP-diacylglycerol biosynthesis
10	Q5EBC7_RAT, G3V631_RAT	Rab GTPase-binding effector protein 2, protein Rabgef1	2	Regulation of inflammatory response
11	CX6A1_RAT, ATPO_RAT, COX5A_RAT	Cytochrome c oxidase subunit 6A1, mitochondrial, ATP synthase subunit O, mitochondrial, cytochrome c oxidase subunit 5A, mitochondrial	3	The oxidase in mitochondrial electron transport
12	K2C1_RAT, M3ZCQ4_RAT, K1C10_RAT	Keratin, type II cytoskeletal 1, 2, 10	3	Regulate the activity of kinases
13	D4A5D7_RAT, F1M7K3_RAT, M0R4E1_RAT	Protein phosphatase 1 regulatory subunit 12C, protein Myl7, myosin light chain 4	3	Myosin regulatory
14	Q5FVG5_RAT, TNNT1_RAT, TNNT3_RAT, D3ZCV0_RAT, G3V885_RAT, Q4PP99_RAT, KNT2_RAT, A2MG_RAT	Tropomyosin 2, slow skeletal muscle troponin T, cardiac troponin I, protein Actn2, myosin-6, cardiac troponin C, T-kininogen 2, alpha-2-macroglobulin	8	Regulation of muscle contraction
15	PDPK1_RAT, Q7TQ70_RAT, FIBB_RAT, PDPK1_RAT, YES_RAT, Q5BK05_RAT, IGG2C_RAT	Protein kinase B, kinase, Ac1873, fibrinogen beta chain, protein kinase B kinase, tyrosine-protein kinase Yes, LOC367586 protein, Ig gamma-2C chain C region	7	Immunological regulation
16	RS15_RAT, RS28_RAT, RL24_RAT, RL32_RAT, NH2L1_RAT	40S ribosomal protein S15, S28, 60S ribosomal protein L24, L32, NHP2-like protein 1	5	Ribosomal protein, translation proteins

3.5 Establishment of pathways

Pathway analysis can provide implications for clinical prevention and therapeutic strategies. Therefore, we analyzed the pathways of DEPs using the KEGG database. We discovered that a total of 101 pathways were involved in PM_{2.5}-induced lung

damage. In particular, 15 pathways were found to be involved in responses to stimuli, inflammatory and immune responses such as calcium signaling, mitogen-activated protein kinase (MAPK) signaling, and AKT/phosphoinositide 3-kinase (AKT/PI3K) signaling.



Table 4 Key pathways responsible to mechanisms of PM_{2.5}

KEGG code	Pathway	DEP number	Proteins	Pathway description
rno05204	Chemical carcinogenesis	1	UDP-glucuronosyltransferase	Chemical carcinogenesis can alter signal-transduction pathways
rno05203	Viral carcinogenesis	1	Protein Actn2	Viruses can contribute to initiation as well as progression of human cancers
rno04612	Antigen processing and presentation	1	Protein LOC103689996	Process and present antigen
rno04152	AMPK signaling pathway	1	PkB kinase	It is caused by metabolic stresses that either interfere with ATP production or that accelerate ATP consumption
rno04146	Peroxisome	2	Sterol carrier protein 2, glycerone-phosphate <i>O</i> -acyltransferase	Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis
rno04010	MAPK signaling pathway	2	MAPK kinase 5, evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial	Involved in various cellular functions, including cell proliferation, differentiation and migration
rno04151	PI3K-AKT signaling pathway	1	Protein kinase B kinase	PI3K-AKT is activated by cellular stimuli or toxic insults and regulates fundamental cellular functions. PI3kinase AKT also regulates F-actin
rno04150	mTOR signaling pathway	1	Protein kinase B kinase	mTOR is activated by the presence of growth factors, amino acids, energy status, stress and oxygen levels to regulate biological processes, including autophagy and protein synthesis
rno04660	T cell receptor signaling pathway	1	Protein kinase B kinase	A key event for an efficient response of the immune system, lead to T-cell proliferation activation, cytokine production and differentiation into effector cells
rno04020	Calcium signaling pathway	1	Protein Thnc1	The influx of Ca ²⁺ from the environment or release from internal stores causes a very rapid and dramatic increase in cytoplasmic calcium concentration, which has been widely exploited for signal transduction
rno04145	Phagosome	1	Tap2 protein	Phagocytosis is the process of taking in relatively large particles by a cell, and is a central mechanism in the tissue remodeling, inflammation, and defense against infectious agents
rno04650	Natural killer cell mediated cytotoxicity	1	CD48 antigen	NK cells are lymphocytes of the innate immune system that are involved in early defenses against both allogeneic (nonself) cells and autologous cells
rno04670	Leukocyte transendothelial migration	3	Protein Actn2, claudin, protein Myl7	Leukocyte migration from the blood into tissues is vital for immune surveillance and inflammation
rno05310	Asthma	1	Eosinophil peroxidase	Asthma is a complex syndrome with many clinical phenotypes in both adults and children
rno05223	Non-small cell lung cancer	1	Protein kinase B kinase	Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer

Activations of calcium signaling, MAPK and AKT/PI3K pathways regulated inflammatory response and activated immune response system, including antigen processing and presentation,^{27,28} T cell and B cell proliferation, natural killer cell (NK cell) mediated cytotoxicity, leukocyte migration and phagocytosis. Based on KEGG analysis and previous literature, we achieved an integral pathway to explain the mechanisms of PM_{2.5}-induced lung damage (Fig. 6). Chemical carcinogenesis

and viral carcinogenesis of PM_{2.5} induced pulmonary disease, such as asthma and lung cancer through the stimulus, inflammatory response and immune response.^{29,30} The first stage of lung damage was the processing and presentation of antigens. Reactive oxygen species (ROS) and microorganisms coated on PM_{2.5} functioned as antigens activating immune response. CD8+ and CD4+ T cells participated in the processing and presentation of antigens through MHC-I and MHC-II,






Fig. 6 An integrated pathway of PM_{2.5}-induced lung damage.

respectively.³¹ The second stage was the activation of inflammation and immunity, such as activation of T lymphocytes cell, B lymphocytes cell and NK cell. Calcium signaling pathway participated in the proliferation of immune cells.³² Subsequently, the immune cells released the active mediators, *i.e.*, the formation of antibody by B cells, chemotactic factors by mast cell and secretory factor killing by T cell. The last stage was the formation of lung injury. Toxic particles induced by eosinophils led to tissue damage and promoted the development of chronic inflammation. On the other hand, NK cells had potent cytotoxic

activity against infectious or neoplastic cells and induced programmed death of lung cells, eventually leading to pulmonary diseases, such as asthma and even lung cancer.³³ The proteins, Tnnc1, MP2K5 and PkB kinase, were involved in calcium signaling, MAPK signaling and PI3K/AKT pathway, respectively.

3.6 Western-blot analysis and biomarker verification

Human lung AEC-II cells were treated with 100 µg mL⁻¹ PM_{2.5} for 72 h, and four differentially significant protein expressions of HMOX1, MP2K5, XRCC1 and A1AG were determined by Western-blot assay (E9PTZ7, KNT2 corresponding antibody were not found). As shown in Fig. 7, PM_{2.5} exposure increased the expression of XRCC1 protein by 1.13 times ($P > 0.05$, not statistically significant), MP2K5 by 1.33 times ($P < 0.05$), HMOX1 by 1.74 times ($P < 0.01$), and A1AG by 1.22 times ($P < 0.05$). Quantitative results were consistent with proteomic analysis. Combined with statistical analysis, MP2K5, HMOX1 and A1AG were used as biomarkers for detecting PM_{2.5}-induced lung injury.




Fig. 7 The expression of significant DEPs in AEC-II cells exposed to PM_{2.5}.

4. Conclusion

In conclusion, we developed a novel integrative system combining a set of experimental models, analytical techniques and bioinformatics analysis tools to investigate the proteomics of PM_{2.5}-induced lung damage. Six significant DEPs were screened as biomarkers, including HMOX1, MP2K5, XRCC1, E9PTZ7, A1AG and KNT2. The results of the GO and STRING program



suggested that oxidative stress stimulus, inflammatory response and immune regulation were the most significant processes in lung injury. KEGG analysis revealed that calcium signaling, MAPK and PI3K/AKT might be involved in the process of PM_{2.5}-induced lung damage. The proteins, Tnnc1, MP2K5 and PkB kinase, were involved in calcium signaling, MAPK signaling and PI3K/AKT pathway, respectively, which provided implications for preventive and therapeutic strategies of PM_{2.5} associated pulmonary diseases such as asthma and lung cancer. Further evidences like gene knockout are also needed. Our present study provide primary information on biomarkers and pathways of PM_{2.5}-induced toxicity in lung tissue and can serve as fundamental research clues for future studies.

Conflicts of interest

The authors declare no competing financial interests.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 31571825, No. 31271979) and Key Experiment Research Foundation for Water Resources and Water Environment of Tianjin (No. YF117100102).

References

- 1 R. J. Huang, Y. Zhang, C. Bozzetti, K. F. Ho, J. J. Cao, Y. Han, K. R. Daellenbach, J. G. Slowik, S. M. Platt, F. Canonaco, P. Zotter, R. Wolf, S. M. Pieber, E. A. Brunns, M. Crippa, G. Ciarelli, A. Piazzalunga, M. Schwikowski, G. Abbazade, J. Schnelle-Kreis, R. Zimmermann, Z. An, S. Szidat, U. Baltensperger, I. El Haddad and A. S. Prevot, *Nature*, 2014, **514**, 218–222.
- 2 C. M. Wong, H. Tsang, H. K. Lai, G. N. Thomas, K. B. Lam, K. P. Chan, Q. S. Zheng, J. G. Ayres, S. Y. Lee, T. H. Lam and T. Q. Thach, *Cancer Epidemiol., Biomarkers Prev.*, 2016, **25**, 839–845.
- 3 G. Sancini, F. Farina, C. Battaglia, I. Cifola, E. Mangano, P. Mantecca, M. Camatini and P. Palestini, *PLoS One*, 2014, **9**, e109685.
- 4 R. Chen, Z. Zhao and H. Kan, *Am. J. Respir. Crit. Care Med.*, 2013, **188**, 1170–1171.
- 5 J. O. Anderson, J. G. Thundiyil and A. Stolbach, *J. Med. Toxicol.*, 2012, **8**, 166–175.
- 6 L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent and A. Jemal, *Ca-Cancer J. Clin.*, 2015, **65**, 87–108.
- 7 A. J. Badyda, J. Grellier and P. Dabrowiecki, *Adv. Exp. Med. Biol.*, 2017, **944**, 9–17.
- 8 A. Colao, G. Muscogiuri and P. Piscitelli, *Int. J. Environ. Res. Public Health*, 2016, **13**, 1–9.
- 9 X. Chen, L. W. Zhang, J. J. Huang, F. J. Song, L. P. Zhang, Z. M. Qian, E. Trevathan, H. J. Mao, B. Han, M. Vaughn, K. X. Chen, Y. M. Liu, J. Chen, B. X. Zhao, G. H. Jiang, Q. Gu, Z. P. Bai, G. H. Dong and N. J. Tang, *Sci. Total Environ.*, 2016, **571**, 855–861.
- 10 Y. Chen, A. Ebenstein, M. Greenstone and H. Li, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 12936–12941.
- 11 L. Curtis, W. Rea, P. Smith-Willis, E. Fenyves and Y. Pan, *Environ. Int.*, 2006, **32**, 815–830.
- 12 K. Hackner, P. Errhalt, M. R. Mueller, M. Speiser, B. A. Marzluf, A. Schulheim, P. Schenk and J. Bilek, *J. Breath Res.*, 2016, **10**, 046003.
- 13 A. Hirai, S. Shinohara, T. Kuwata, M. Takenaka, Y. Chikaishi, S. Oka, K. Kuroda, N. Imanishi and F. Tanaka, *Surgical Case Reports*, 2016, **2**, 46.
- 14 S. L. Shirran and C. H. Botting, *J. Proteomics*, 2010, **73**, 1391–1403.
- 15 Y. S. Zhou and W. N. Chen, *J. Proteomics*, 2011, **75**, 511–516.
- 16 X. T. Zhong, Z. Q. Wang, R. Y. Xiao, Y. Q. Wang, Y. Xie and X. P. Zhou, *J. Proteomics*, 2017, **152**, 88–101.
- 17 P. Mantecca, F. Farina, E. Moschini, D. Gallinotti, M. Gualtieri, A. Rohr, G. Sancini, P. Palestini and M. Camatini, *Toxicol. Lett.*, 2010, **198**, 244–254.
- 18 X. Deng, W. Rui, F. Zhang and W. Ding, *Cell Biol. Toxicol.*, 2013, **29**, 143–157.
- 19 A. E. Quaglio, A. C. Castilho and L. C. Di Stasi, *Life Sci.*, 2015, **136**, 60–66.
- 20 Z. Zhou, Y. Liu, F. Duan, M. Qin, F. Wu, W. Sheng, L. Yang, J. Liu and K. He, *PLoS One*, 2015, **10**, e0138267.
- 21 J. K. Horton, D. F. Stefanick, N. R. Gassman, J. G. Williams, S. A. Gabel, M. J. Cuneo, R. Prasad, P. S. Kedar, E. F. Deroose, E. W. Hou, R. E. London and S. H. Wilson, *DNA Repair*, 2013, **12**, 774–785.
- 22 Y. Li, O. Bai, J. Cui and W. Li, *Eur. J. Med. Genet.*, 2016, **59**, 91–103.
- 23 S. Diaz-Moran, M. Palencia, C. Mont-Cardona, T. Canete, G. Blazquez, E. Martinez-Membrives, R. Lopez-Aumatell, M. Sabariego, R. Donaire, I. Moron, C. Torres, J. A. Martinez-Conejero, A. Tobena, F. J. Esteban and A. Fernandez-Teruel, *Behav. Brain Res.*, 2013, **257**, 129–139.
- 24 G. X. Ren, C. E. Wu, C. Teng and Y. Yao, *Food Agric. Immunol.*, 2018, **29**(1), 953–963.
- 25 S. Michael, M. Montag and W. Dott, *Environ. Pollut.*, 2013, **183**, 19–29.
- 26 U. S. Akhtar, R. D. McWhinney, N. Rastogi, J. P. Abbatt, G. J. Evans and J. A. Scott, *Inhalation Toxicol.*, 2010, **22**(suppl. 2), 37–47.
- 27 J. Cao, G. Qin, R. Shi, F. Bai, G. Yang, M. Zhang and J. Lv, *J. Appl. Toxicol.*, 2016, **36**, 609–617.
- 28 R. Su, X. Jin, W. Zhang, Z. Li, X. Liu and J. Ren, *Chemosphere*, 2016, **167**, 444–453.
- 29 R. Ghosh, P. Rossner, K. Honkova, M. Dostal, R. J. Sram and I. Hertz-Picciotto, *Environ. Int.*, 2016, **87**, 94–100.
- 30 L. Yang, G. Liu, Z. Lin, Y. Wang, H. He, T. Liu and D. W. Kamp, *Environ. Toxicol.*, 2016, **31**, 923–936.
- 31 R. D. F. E. Silva, L. F. G. R. Ferreira, M. Z. Hernandez, M. E. F. De Brito, B. C. De Oliveira and A. A. Da Silva, *Front. Immunol.*, 2016, **7**, 327.
- 32 P. S. Lakey, T. Berkemeier, H. Tong, A. M. Arangio, K. Lucas, U. Poschl and M. Shiraiwa, *Sci. Rep.*, 2016, **6**, 32916.
- 33 M. Voss and Y. T. Bryceson, *Clin. Immunol.*, 2015, **15**, 1–14.

